CLCC1 Antibody - BSA Free

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793]

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793] - Staining of human cerebellum shows weak positivity in neuronal processes.

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793]

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793] - Staining of human endometrium shows strong cytoplasmic positivity in glandular cells.

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793]

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793] - Staining of human kidney shows moderate cytoplasmic positivity in cells in tubules.

Western Blot: CLCC1 Antibody [NBP1-82793]

CLCC1-Antibody-Knockdown-Validated-NBP1-82793-img0021.jpg

Western Blot: CLCC1 Antibody [NBP1-82793] -

Western Blot: CLCC1 Antibody [NBP1-82793] - CLCC1 siRNA interference in ARPE19 cells.(a) Western Blot of SiRNA treated ARPE19 cell lysates probed with CLCC1 antibodies. Lane 1, untransfected lysate; lane 2, transfected with RNAi Max transfection reagent only; lanes 3–12, Increasing CLCC1 & control siRNA amounts from 10 pmol (lanes 3,4) to 70 pmol (lanes 11, 12). CLCC1 proteins migrate at the predicted MW of 67 kDa. The blot shows a dose dependent reduction of CLCC1 protein expression in CLCC1 but not control siRNA treated ARPE19 cells to about 20% of normal. (b) TUNEL assay after siRNA transfection. Left: TUNEL-positive apoptotic cells (green), Second: CLCC1 (red), Third: DAPI (blue, nucleus). Although there is some variation in intensity of individual cells, probably based on cell size, shape, & orientation, staining for CLCC1 is lower overall in the CLCC1 siRNA treated cells than the control siRNA, control, or DNase 1 cells, consistent with the Western blot in Fig 5a. About 10% of CLCC1 siRNA transfected cells were apoptotic (arrows) but there is minimal apoptosis in control siRNA or untransfected cells. DNase I treated cells were 100% TUNEL-positive. Overlays of images from the first three columns are shown in the right column labeled Merged. Scale Bar: 20 μm. (c) Down regulation of CLCC1 induced apoptosis in nearly 10% of the cells (*** P<0.0001, t = 14.63) as compared to approximately 1% of cells treated with the control siRNA & less than 1% of untreated cells. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30157172), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: CLCC1 Antibody - BSA Free [NBP1-82793] -

CLCC1 siRNA interference in ARPE19 cells.(a) Western Blot of SiRNA treated ARPE19 cell lysates probed with CLCC1 antibodies. Lane 1, untransfected lysate; lane 2, transfected with RNAi Max transfection reagent only; lanes 3–12, Increasing CLCC1 and control siRNA amounts from 10 pmol (lanes 3,4) to 70 pmol (lanes 11, 12). CLCC1 proteins migrate at the predicted MW of 67 kDa. The blot shows a dose dependent reduction of CLCC1 protein expression in CLCC1 but not control siRNA treated ARPE19 cells to about 20% of normal. (b) TUNEL assay after siRNA transfection. Left: TUNEL-positive apoptotic cells (green), Second: CLCC1 (red), Third: DAPI (blue, nucleus). Although there is some variation in intensity of individual cells, probably based on cell size, shape, and orientation, staining for CLCC1 is lower overall in the CLCC1 siRNA treated cells than the control siRNA, control, or DNase 1 cells, consistent with the Western blot in Fig 5a. About 10% of CLCC1 siRNA transfected cells were apoptotic (arrows) but there is minimal apoptosis in control siRNA or untransfected cells. DNase I treated cells were 100% TUNEL-positive. Overlays of images from the first three columns are shown in the right column labeled Merged. Scale Bar: 20 μm. (c) Down regulation of CLCC1 induced apoptosis in nearly 10% of the cells (*** P<0.0001, t = 14.63) as compared to approximately 1% of cells treated with the control siRNA and less than 1% of untreated cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30157172), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.